接受卡非佐米或硼替佐米联合来那度胺和地塞米松治疗的新诊断多发性骨髓瘤患者的静脉血栓栓塞风险
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone.
作者信息
Loncharich Alexa J, Fiala Mark A, Slade Michael J, Vickroy Angela, Kavanaugh Margaret, Wilson Carmen, Schroeder Mark A, Stockerl-Goldstein Keith, Vij Ravi, Sanfilippo Kristen M
机构信息
Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO.
Division of Oncology, Washington University School of Medicine, St. Louis, MO.
出版信息
Clin Lymphoma Myeloma Leuk. 2023 Nov;23(11):825-828. doi: 10.1016/j.clml.2023.07.009. Epub 2023 Jul 23.
BACKGROUND
Multiple myeloma (MM), as well as some treatments for MM, increase the risk of venous thromboembolism (VTE). Prior literature suggests carfilzomib, lenalidomide, and dexamethasone (KRd) may have a higher incidence of thromboembolic events compared with bortezomib, lenalidomide, and dexamethasone (VRd). We aimed to evaluate VTE risk with KRd induction compared to VRd at a large academic medical center in the United States.
MATERIALS AND METHODS
We retrospectively reviewed patients with newly diagnosed MM presenting at a single institution. Patients were followed for objectively diagnosed VTE events for 6 months following the start of induction therapy.
RESULTS
A total of 209 patients were included, with 69 (33%) receiving KRd and 140 (67%) receiving VRd. Overall, 18 patients (9%) had a VTE event, with 5 (7%) in the KRd cohort and 13 (9%) in the VRd cohort (P = .80). Treatment with KRd was not associated with an increased risk of VTE compared to VRd (HR 0.74; 95% CI 0.26-2.08; P = .57).
CONCLUSION
In this cohort, KRd was not associated with an increase in VTE risk compared to VRd, contrary to prior literature.
背景
多发性骨髓瘤（MM）以及MM的一些治疗方法会增加静脉血栓栓塞（VTE）的风险。先前的文献表明，与硼替佐米、来那度胺和地塞米松（VRd）相比，卡非佐米、来那度胺和地塞米松（KRd）可能有更高的血栓栓塞事件发生率。我们旨在在美国一家大型学术医疗中心评估与VRd相比，KRd诱导治疗时的VTE风险。
材料与方法
我们回顾性分析了在单一机构就诊的新诊断MM患者。在诱导治疗开始后，对患者进行6个月的客观诊断VTE事件随访。
结果
共纳入209例患者，其中69例（33%）接受KRd治疗，140例（67%）接受VRd治疗。总体而言，18例患者（9%）发生了VTE事件，KRd组有5例（7%），VRd组有13例（9%）（P = 0.80）。与VRd相比，KRd治疗与VTE风险增加无关（HR 0.74；95% CI 0.26 - 2.08；P = 0.57）。
结论
在该队列中，与VRd相比，KRd与VTE风险增加无关，这与先前的文献报道相反。
Zotero 插件